Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, 26 Week, Multicentre, Randomized Double Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy and Safety of Tolterodine, Pregabalin and a Tolterodine-Pregabalin Combination for Idiopathic Overactive Bladder

NCT00746681 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00746681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00746681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, 26 Week, Multicentre, Randomized Double Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy and Safety of Tolterodine, Pregabalin and a Tolterodine-Pregabalin Combination for Idiopathic Overactive Bladder
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2005
Completion date
November 30, 2006
Enrollment
188 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder